CD19 and neoplasm: Therefore, CD16-directed bispecific (eg, CD16 and CD19) or trispecific (eg, CD16 and two tumor antigens CD19 and CD22 or one tumor antigen and an IL-15 linker) antibodies or scFv have been developed.37